-
2
-
-
77956401725
-
Equipoise lost: Ethics, costs, and the regulation of cancer clinical research
-
Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 2010;28:2925-35.
-
(2010)
Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology
, vol.28
, pp. 2925-2935
-
-
Stewart, D.J.1
Whitney, S.N.2
Kurzrock, R.3
-
3
-
-
84876096711
-
Fool's gold, lost treasures, and the randomized clinical trial
-
Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 2013;13:193.
-
(2013)
BMC Cancer
, vol.13
, pp. 193
-
-
Stewart, D.J.1
Kurzrock, R.2
-
4
-
-
78349287749
-
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies
-
Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5557-5563
-
-
Cheng, S.K.1
Dietrich, M.S.2
Dilts, D.M.3
-
6
-
-
84875360328
-
Experimental designs for small randomised clinical trials: An algorithm for choice
-
Cornu C, Kassai B, Fisch R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet Journal of Rare Diseases 2013;8:48.
-
(2013)
Orphanet Journal of Rare Diseases
, vol.8
, pp. 48
-
-
Cornu, C.1
Kassai, B.2
Fisch, R.3
-
7
-
-
84881482075
-
Sustainable rare diseases business and drug access: No time for misconceptions
-
Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet Journal of Rare Diseases 2013;8:109.
-
(2013)
Orphanet Journal of Rare Diseases
, vol.8
, pp. 109
-
-
Rollet, P.1
Lemoine, A.2
Dunoyer, M.3
-
8
-
-
79958036418
-
Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer
-
Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer. JAMA 2011;305:2320-6.
-
(2011)
JAMA
, vol.305
, pp. 2320-2326
-
-
Kesselheim, A.S.1
Myers, J.A.2
Avorn, J.3
-
9
-
-
84882953749
-
Developing standards for breakthrough therapy designation in oncology
-
Horning SJ, Haber DA, Selig WK, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013;19:4297-304.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4297-4304
-
-
Horning, S.J.1
Haber, D.A.2
Selig, W.K.3
-
10
-
-
84895800854
-
Clinical trials in rare disorders: Considering a toolkit for developing evidence based treatment
-
Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. Clinical trials in rare disorders: Considering a toolkit for developing evidence based treatment. J Popul Ther Clin Pharmacol 2014;Vol 21(1):e66-e78.
-
(2014)
J Popul Ther Clin Pharmacol
, vol.21
, Issue.1
-
-
Abrahamyan, L.1
Diamond, I.R.2
Johnson, S.R.3
Feldman, B.M.4
-
11
-
-
34248204234
-
Uncommon tumors and exceptional therapies: Paradox or paradigm?
-
Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007;6:1175-9.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1175-1179
-
-
Braiteh, F.1
Kurzrock, R.2
-
12
-
-
84862823259
-
Molecular pathology of lung cancer: Key to personalized medicine
-
Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25:347-69.
-
(2012)
Modern Pathology: An official journal of the United States and Canadian Academy of Pathology, Inc
, vol.25
, pp. 347-369
-
-
Cheng, L.1
Alexander, R.E.2
McLennan, G.T.3
-
13
-
-
84882576021
-
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma
-
Matsuura S, Shinmura K, Kamo T, et al. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncology Reports 2013;30:1675-80.
-
(2013)
Oncology Reports
, vol.30
, pp. 1675-1680
-
-
Matsuura, S.1
Shinmura, K.2
Kamo, T.3
-
14
-
-
84881663252
-
KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung
-
Borrelli N, Giannini R, Proietti A, et al. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer 2013;81:377-81.
-
(2013)
Lung Cancer
, vol.81
, pp. 377-381
-
-
Borrelli, N.1
Giannini, R.2
Proietti, A.3
-
15
-
-
33750072289
-
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer
-
Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 2006;11:687-92.
-
(2006)
Respirology
, vol.11
, pp. 687-692
-
-
Ahmed, S.M.1
Salgia, R.2
-
16
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine 2011;3:75ra26.
-
(2011)
Science Translational Medicine
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
-
18
-
-
70350135946
-
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development
-
Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J 2009;15:366-73.
-
(2009)
Cancer J
, vol.15
, pp. 366-373
-
-
Vidaurre, T.1
Wilkerson, J.2
Simon, R.3
Bates, S.E.4
Fojo, T.5
-
21
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
23
-
-
84878066430
-
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
-
Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19:2688-98.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2688-2698
-
-
Coffee, E.M.1
Faber, A.C.2
Roper, J.3
-
25
-
-
79956318148
-
Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer
-
Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Archives of Pathology & Laboratory Medicine 2011;135:655-64.
-
(2011)
Archives of Pathology & Laboratory Medicine
, vol.135
, pp. 655-664
-
-
Mino-Kenudson, M.1
Mark, E.J.2
-
27
-
-
0032748041
-
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
-
Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 1999;81:760-8.
-
(1999)
Br J Cancer
, vol.81
, pp. 760-768
-
-
Newell, D.R.1
Burtles, S.S.2
Fox, B.W.3
Jodrell, D.I.4
Connors, T.A.5
-
28
-
-
1942518871
-
The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies
-
Newell DR, Silvester J, McDowell C, Burtles SS. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer 2004;40:899-906.
-
(2004)
Eur J Cancer
, vol.40
, pp. 899-906
-
-
Newell, D.R.1
Silvester, J.2
McDowell, C.3
Burtles, S.S.4
-
29
-
-
0035683744
-
The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry collaborations in new agent development
-
Ansher SS, Scharf R. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry collaborations in new agent development. Annals of the New York Academy of Sciences 2001;949:333-40.
-
(2001)
Annals of the New York Academy of Sciences
, vol.949
, pp. 333-340
-
-
Ansher, S.S.1
Scharf, R.2
|